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INTRODUCTION
In 2008, the Korean Radiation Oncology Group (KROG) 
initiated a prospective phase III randomized trial (KROG 08-
06) designed to investigate the effect of internal mammary 
node irradiation (IMNI) on disease-free survival (DFS) and 
toxicity in breast cancer patients. Until that time, no consen-
sus existed regarding the use of IMNI in postmastectomy ra-
diotherapy or radiotherapy after breast-conserving surgery 
(BCS). Inclusion of the internal mammary nodes (IMNs) in 
breast cancer radiotherapy is mainly dependent on the prefer-
ences of the treating radiation oncologists. A Korean pattern-
of-care study showed that approximately 50% of patients re-
ceived IMNI during postmastectomy radiotherapy [1]. Vari-
able patterns of clinical practice regarding IMNI, which were 
culture-driven not evidence-based, have been reported [2,3]. 
Because IMNI may increase radiation exposure to critical 
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Purpose: The aim of this study is to present the incidence of ra-
diation pneumonitis (RP) reported within 6 months after treat-
ment for breast cancer with or without internal mammary node 
irradiation (IMNI). Methods: In the Korean Radiation Oncology 
Group (KROG) 08-06 phase III randomized trial, patients who 
were node-positive after surgery were randomly assigned to re-
ceive radiotherapy either with or without IMNI. A total of 747 pa-
tients were enrolled, and three-dimensional treatment planning 
with computed tomography simulation was performed for all pa-
tients. Of the 747 patients, 722 underwent chest X-rays before 
and within 6 months after radiotherapy. These 722 patients un-
derwent evaluation, and RP was diagnosed on the basis of 
chest radiography findings and clinical symptoms. The relation-
ship between the incidence of RP and clinical/dosimetric para-
meters was analyzed. Results: RP developed in 35 patients (4.8%), 
including grade 1 RP in 26 patients (3.6%), grade 2 RP in nine 
patients (1.2%); there was no incidence of grade 3 or higher RP. 
Grade 2 RP cases were observed in only the IMNI group. The 
risk of developing RP was influenced by IMNI treatment; pneu-
monitis occurred in 6.5% of patients (n=23/356) who underwent 
IMNI and in 3.3% of patients (n=12/366) who did not (p=0.047). 
The differences in lung dosimetric parameters (mean lung dose, 
V10–40) were statistically significant between the two groups. 
Conclusion: IMNI treatment resulted in increased radiation expo-
sure to the lung and a higher rate of RP, but the incidence and 
severity of RP was minimal and acceptable. This minor impact 
on morbidity should be balanced with the impact on survival 
outcome in future analyses.
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organs, new studies must determine whether the expected 
benefits of elective IMNI is worth the risk of late toxicity to 
critical organs, such as the lungs and heart [4]. In the European 
Organisation for Research and Treatment of Cancer (EORTC) 
22922/10925 trial, instances of pulmonary toxicity were sig-
nificantly higher in the IM-MS (internal mammary and medial 
supraclavicular chain) treatment group than in the control 
group [5]. The National Cancer Institute of Canada Clinical 
Trial Group MA.20 trial demonstrated improved DFS in 
patients with one to three positive nodes with the addition of 
regional nodal irradiation, including IMNI. However, this 
additional irradiation was associated with an increase in the 
incidence of grade 2 or higher pneumonitis (1.3% vs. 0.2%) [6].
Upon its completion in February 2013, KROG 08-06 had 
enrolled a total of 747 patients. In this study, we reviewed col-
lected data from the evaluable 722 patients and present the in-
cidence of radiation pneumonitis (RP) reported within 6 
months after radiotherapy with or without IMNI.
METHODS
Randomization and patient characteristics 
Eligible patients were pathologically confirmed to have axil-
lary node-positive breast cancer after surgery consisting of ei-
ther modified radical mastectomy (MRM) or BCS, regardless 
of histologic type. All patients underwent axillary dissection, 
in which eight or more lymph nodes were identified. Patients 
were stratified according to N stage (N1 vs. N2 or N3) and 
type of surgery (breast conservation vs. mastectomy), and 
then were randomly assigned to receive radiotherapy either 
with or without IMNI (Figure 1). Three hundred and one pa-
tients were diagnosed with pathologic stage N1 disease, and 
416 patients were diagnosed with N2 or N3 disease. Three 
hundred and sixty-one patients were treated with BCS, and 
the remaining 356 patients were treated with MRM. Among 
the patients with BCS, 178 were randomly assigned to the 
IMNI group, and 183 were randomly assigned to the non-
IMNI group. Among the patients with MRM, 173 were ran-
domly assigned to the IMNI group, and 183 patients were as-
signed to the non-IMNI group. All patients had unilateral in-
vasive breast cancer and were eligible for adjuvant chemother-
apy with or without hormonal therapy. Patients who received 
neoadjuvant systemic therapy or had a previous history of 
cancer or distant metastasis were excluded. 
Between November 2008 and February 2013, we enrolled 
747 patients from the 12 participating institutions in Korea. 
The study protocol was approved by the institutional review 
board (IRB approval number: 4-2008-0263), and all patients 
provided written informed consent. Twenty-five patients 
(3.3%) who had not undergone chest X-ray within 6 months 
of radiotherapy completion were excluded from the analysis, 
leaving 722 analyzable patients. The characteristics of the pa-
tients in this study are presented in Table 1. The median pa-
tient age was 48 years (range, 28–77 years) in both groups. 
The majority of the patients enrolled (99.6%) had Eastern Co-
operative Oncology Group performance scores of 0 or 1. The 
non-IMNI group included a significantly higher percentage of 
patients with ductal carcinoma and a progesterone receptor-
negative status compared with the IMNI group (p= 0.003 and 
p= 0.030, respectively). Other patient characteristics were not 
significantly different between the two groups.
Radiation treatment
Radiation was administered once per day at a dose of 1.8–2 
Gy, up to a total dose of 45–50.4 Gy; additionally, 381 patients 
(52.8%) received boost radiotherapy to the primary tumor bed 
with a median dose of 10 Gy (range, 9–16 Gy) in five fractions. 
All patients received supraclavicular irradiation, as routinely 
Mastectomy & ALND
747 Randomization
210 BCS 151 BCS91 MRM 265 MRM
78 IMNI 73 Non-IMNI 128 IMNI 137 Non-IMNI46 Non-IMNI45 IMNI110 Non-IMNI100 IMNI
301 N1 416 N2, N3
Figure 1. KROG-08-06 trial diagram. 
KROG=Korean Radiation Oncology Group; ALND=axillary lymph node dissection; BCS=breast-conserving surgery; MRM=modified radical mas-
tectomy; IMNI= internal mammary node irradiation.
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Table 1. Patients and tumor characteristics
Characteristic Total patients (n=722), No. (%) IMNI (n=356), No. (%) Non-IMNI (n=366), No. (%) p-value
Age (yr) 0.357
   Median (range)     48 (28–77)   48 (28–77)   48 (31–74)
   <50   410 (56.9) 208 (58.4) 202 (55.2)
   ≥50 311 (43) 147 (41.3) 164 (44.8)
   Missing    1 (0.1) 1 (0.3)
Performance status 0.129
   ECOG 0  609 (84.3) 310 (87.1) 299 (81.7)
   ECOG 1  110 (15.2)  45 (12.6)  65 (17.8)
   ECOG 2–3   2 (0.2) 0  2 (0.5) 
   Missing   1 (0.1) 1 (0.3)
Type of surgery 0.879
   Mastectomy  356 (49.3) 173 (48.6) 183 (50)
   Breast-conserving 361 (50) 178 (50.0) 183 (50)
   Missing    5 (0.7) 5 (1.4)
Laterality 0.906
   Right  366 (50.7) 181 (50.8) 185 (50.5)
   Left  355 (49.2) 174 (48.9) 181 (49.5)
   Missing   1 (0.1) 1 (0.3)
Histologic type 0.003
   IDC 656 (90.9) 310 (87.1) 346 (94.5)
   Others 61 (8.4)  41 (11.5)  20 (5.5)
   Missing  5 (0.7) 5 (1.4)
T stage 0.665
   T1 226 (31.3) 117 (32.9) 109 (29.8)
   T2 401 (55.5) 188 (52.8) 213 (58.2)
   T3 84 (11.6)  43 (12.1)  41 (11.2)
   T4 6 (0.8)  3 (0.8)  3 (0.8)
   Missing 5 (0.7) 5 (1.4)
N stage 0.937
   N1 301 (41.7) 145 (40.7) 156 (42.6)
   N2 259 (35.9) 128 (36.0) 131 (35.8)
   N3 157 (21.7)  78 (21.9)  79 (21.6)
   Missing  5 (0.7) 5 (1.4)
Histologic grade 0.471
   I–II 377 (54.8) 191 (53.6) 186 (50.8)
   III 311 (43.1) 143 (40.2) 168 (45.9)
   Unknown 34 (4.7) 22 (6.2) 12 (3.3)
ER status 0.109
   Positive 513 (71.1) 262 (73.6) 251 (68.6)
   Negative 196 (27.1) 84 (23.6) 112 (30.6)
   Unknown 13 (1.8) 10 (2.8)   3 (0.8)
PR status 0.03
   Positive 449 (62.2) 234 (65.7) 215 (58.7)
   Negative 261 (36.1) 112 (31.5) 149 (40.7)
   Unknown 12 (1.7) 10 (2.8)   2 (0.5)
HER2 status 0.222
   Negative 476 (65.9) 237 (66.6) 239 (65.3)
   Positive 223 (30.9) 104 (29.2) 119 (32.5)
   Unknown 23 (3.2) 15 (4.2)   8 (2.2)
Chemotherapy 0.663
   Yes  708 (98.0) 346 (97.2) 362 (98.9)
   No 7 (1)  4 (1.1)   3 (0.8)
   Missing 7 (1) 6 (1.7) 1 (0.3)
Hormonal therapy 0.083
   Yes 481 (66.6) 246 (69.1) 235 (64.2)
   No 235 (32.5) 104 (29.2) 131 (35.8)
   Missing  6 (0.8) 6 (1.7)
IMNI = internal mammary node irradiation; ECOG =Eastern Cooperative Oncology Group; IDC = invasive ductal carcinoma; ER =estrogen receptor; 
PR=progesterone receptor; HER2=human epidermal growth factor receptor 2.
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performed for node-positive disease. Each patient underwent 
computed tomography (CT)-based simulation, and structures 
were manually contoured on CT scan slices. This protocol con-
tained no strict guidelines on radiotherapy technique; the 
techniques were determined at the discretion of the physician, 
and included the reverse hockey stick, standard tangent, par-
tial wide tangent, and photon/electron combination tech-
niques. A detailed distribution of the patients according to ra-
diotherapy technique is shown in Table 2. In the MRM-IMNI 
group, the partial wide tangent (n= 84, 48.5%) was the most 
commonly used technique, followed by the reverse hockey 
stick method (n= 51, 29.4%). In the BCS group, the partial 
wide tangent method (n= 101, 58.7%) and the photon/elec-
tron combination method (n= 71, 41.2%) were used for IMN 
irradiation. In the non-IMNI group, the most commonly used 
radiotherapy technique was the standard tangent method for 
both MRM patients (n= 132, 72.1%) and BCS patients (n=  
182, 100%).
Radiation pneumonitis assessment
After completion of radiotherapy, follow-up examinations 
including chest X-rays and physical examinations were ob-
tained within 6 months. Chest X-rays obtained at baseline 
(before radiotherapy) were compared with those obtained 
within 6 months after treatment to determine RP levels. RP-
related symptoms, such as cough, dyspnea, and the incidence 
of steroid treatment, were also identified and recorded. RP 
grade was scored on a scale of 0–5, based on the Radiation 
Therapy Oncology Group/EORTC toxicity criteria as follows: 
grade 0= no change over baseline; 1= asymptomatic or mild 
symptoms (dry cough), slight radiographic appearances; 
2 = moderate symptomatic fibrosis or pneumonitis (severe 
cough), low-grade fever, patch radiographic appearances; 
3= severe symptomatic fibrosis or pneumonitis, dense radio-
graphic appearance; 4= severe respiratory insufficiency, con-
tinuous O2, assisted ventilation; 5= death. To avoid any inter-
observer variation between the 12 participating institutions, 
two radiation oncologists on-site visited and reviewed all ab-
normal chest X-ray findings and assessed them together.
Dosimetric analysis
To identify predictive factors associated with RP develop-
ment, clinical variables and dosimetric parameters were ana-
lyzed via univariate analysis using the Pearson chi-square test. 
Dosimetric parameters such as mean lung dose (MLD), V10, 
V20, V30, and V40 were included in the analysis, and the cor-
relation with RP was analyzed using the Student t-test. Addi-
tionally, the significance of the association between treatment 
assignment and patient characteristics was assessed using the 
chi-square test. Statistical analysis was carried out using SPSS 
version 18.0 (SPSS Inc., Chicago, USA). A p-value ≤ 0.05 was 
considered statistically significant.
RESULTS
Incidence of radiation pneumonitis 
The incidence of RP was higher in the IMNI group (Table 
3). Of the 722 patients, RP developed in 35 patients (4.8%), 
including 26 patients (3.6%) with grade 1 RP and nine pa-
tients (1.2%) with grade 2 RP. No cases of grade 3 or higher 
RP were found. All grade 2 RP cases developed in the IMNI 
group. RP occurred in 6.5% (n= 23/356) of patients who were 
treated with IMNI and 3.3% (n= 12/366) of those who were 
treated without IMNI (p= 0.047). However, most RP cases 
were asymptomatic minimal pulmonary radiologic changes 
defined as grade 1. Of the 26 patients with grade 1 RP, only six 
patients experienced mild dry cough, which improved spon-
taneously. In all grades of RP, most radiologic changes devel-
oped 2 to 3 months into the follow-up period after radiation 
treatment.
Table 2. Radiotherapy techniques used in each treatment group and 
incidence of radiation pneumonitis
RT technique
IMNI 
No. (%)
Non-IMNI 
No. (%)
No. of RP 
(IMNI/non-IMNI)
MRM (n=356)
   Reverse hockey stick 51 (29.4) 50 (27.3) 10 (7/3)
   Standard tangent 0 132 (72.1) 5 (0/5)
   Partial wide tangent 84 (48.5) 0 9 (9/0)
   Photon/electron 
      combination
38 (21.9) 1 (0.5) 2 (2/0)
BCS (n=354)
   Standard tangent 0 182 (100.0) 4 (0/4)
   Partial wide tangent 101 (58.7) 0 4 (4/0)
   Photon/electron 
      combination
71 (41.2) 0 1 (1/0)
RT =radiation therapy; IMNI = internal mammary node irradiation; RP =  
radiation pneumonitis; MRM=modified radical mastectomy; BCS=breast-
conserving surgery.
Table 3. Incidence of radiation pneumonitis by treatment groups
Total patients  
(n=722) 
No. (%) 
IMNI  (n=356) 
No. (%)
Non-IMNI 
(n=366) 
No. (%)  
No RP 687 (95.2) 333 (93.5) 354 (96.7)
RP 35 (4.8) 23 (6.5) 12 (3.3)
   G1 26 (3.6) 14 (3.9) 12 (3.3)
   G2 9 (1.2) 9 (2.5) 0 
   G3 or higher 0 0 0 
IMNI= internal mammary node irradiation; RP=radiation pneumonitis.
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With respect to radiotherapy techniques, the patterns of RP 
incidence differed between the two study arms (Table 2). 
Among the 23 patients who developed RP in the IMNI group, 
13 patients (n= 13/185, 7.0%) developed RP after undergoing 
treatment with the partial wide tangent method, and seven 
patients (n = 7/51, 13.7%) developed RP after the reverse 
hockey stick method. The others (n= 3/109, 2.8%) developed 
RP after the photon/electron combination method. In the 
non-IMNI group, 12 patients developed RP, including nine 
patients (n= 9/314, 2.9%) after the standard tangent method 
and three patients (n= 3/50, 6.0%) after the reverse hockey 
stick method. The overall incidence of RP after the partial 
wide tangent method (13 patients) was similar to that after the 
reverse hockey stick method (10 patients), but the percentage 
of RP patients treated with each technique were 7.0% (n =  
13/185) and 9.9% (n= 10/101), respectively.
Dosimetric parameters
All dosimetric parameters were significantly different be-
tween treatment groups (Figure 2). The MLD was 17.66± 5.33 
Gy with IMNI and 13.29± 4.37 Gy without IMNI (p< 0.001). 
The V10 and V20 with IMNI were 45.68% ± 18.19% and 
34.94% ± 12.15%, respectively, and 31.71% ± 12.87% and 
25.49%± 10.53, respectively, without IMNI. The V30 and V40 
with IMNI were 27.48%± 8.86% and 19.40%± 6.92%, respec-
tively, and 21.07%± 8.81% and 14.65%± 6.67%, respectively, 
without IMNI. 
Univariate analysis of dosimetric parameters for predicting 
the development of RP showed that all dosimetric parameters 
were significantly different between the RP and non-RP groups 
(Figure 3A). In the RP group, the MLD was 17.88± 5.75 Gy, 
and the V10, V20, V30, and V40 were 45.31%±15.69%, 36.20%±  
11.96%, 29.47%± 9.73%, and 21.54%± 8.67%, respectively. In 
the non-RP group, the MLD was 15.38± 5.30 Gy, and the V10, 
V20, V30, and V40 were 38.38%± 17.25%, 29.93%± 12.26%, 
24.02%± 9.30%, and 16.80%± 7.04%, respectively. However, 
dosimetric parameters were not significantly different between 
grade 1 and grade 2 RP patients (Figure 3B).
DISCUSSION
The use of IMNI has been debated, but several reports have 
provided evidence that it improves survival in patients with 
breast cancer [7,8]. A previous retrospective study from our 
institution reported a long-term DFS advantage following 
IMNI in postoperative patients [9]. Although more studies are 
needed to clearly define the role of IMNI in long-term surviv-
al and toxicity, the findings of this retrospective study showed 
that IMNI was obviously effective in patients with N2 disease 
and patients with inner/central tumors. However, there is no 
consensus regarding whether IMNs should be treated, be-
Figure 2. Dosimetric parameters of both internal mammary node irradi-
ation (IMNI) and non-IMNI groups. All dosimetric parameters (V10–40) 
were significantly different between treatment groups. Data are the 
mean±SD. 
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Figure 3. Dosimetric parameters in the patients with radiation pneumo-
nitis. All dosimetric parameters were significantly different between the 
radiation pneumonitis (RP) and non-RP groups (A), not significantly dif-
ferent between grade 1 and grade 2 RP (B). Data are the mean±SD. 
70
60
50
40
30
20
10
0
 V10 V20 V30 V40
Dosimetric parameters
%
A
 RP(−)
 RP(+)
p=0.027
p=0.005
p=0.001
p<0.001
70
60
50
40
30
20
10
0
 V10 V20 V30 V40
Dosimetric parameters
%
B
 Grade 1 RP
 Grade 1 RP
p=0.809
p=0.945
p=0.945
p=0.868
280  Jinhyun Choi, et al.
http://ejbc.kr http://dx.doi.org/10.4048/jbc.2016.19.3.275
cause of the possible increase in the risk for late toxicity. As a 
result of the anatomic location of IMNs, IMNI increases the 
exposure of critical organs, such as the lungs and heart, to ra-
diation.
In this study, we investigated lung toxicity, which may lead 
to deterioration of the patient’s performance status or quality 
of life. We specifically examined RP occurring within 6 
months of treatment and its association with IMNI. RP is a 
common type of toxicity caused by radiation exposure to the 
lung and usually appears within 6 months of the completion 
of radiotherapy. Clinical symptoms, including cough and low-
grade fever, occur following completion of the radiotherapy 
course, and can also be seen as nonspecific infiltration on 
chest X-rays. The rate of pneumonitis may be also influenced 
by systemic therapy [10,11]. Various techniques to irradiate 
the IMN while minimizing normal tissue irradiation have 
been suggested [12]. We previously reported that the partial 
wide tangent method is the best technique for patients under-
going BCS because of the IMN coverage involved with this 
method and because of the reduced dose to the lungs and 
heart. However, the photon/electron combination method 
showed better isodose distribution in some patients [13]. The 
developments in radiotherapy techniques and the availability 
of three-dimensional (3D) treatment planning have allowed 
us to more precisely and safely irradiate IMN. In our country, 
3D treatment planning with CT simulation has been used 
since the mid-2000s; therefore, all patients enrolled in this 
study had undergone CT simulation and 3D treatment plan-
ning. In this study, various radiotherapy techniques were al-
lowed at the discretion of the treating radiation oncologists. In 
the IMNI treatment group, the most commonly used tech-
nique was the partial wide tangent method for both MRM 
and BCS. The reverse hockey stick method was exclusively 
used for MRM cases, both in the IMNI and non-IMNI 
groups. 
The incidence of symptomatic RP (grade ≥ 2) was reported 
as 2.3% after whole breast and supraclavicular lymph node 
treatment without IMNI, and 3% after breast irradiation using 
the partial wide tangent technique, which includes the first 
three IMNs, in single-institution studies [14,15]. As a multi-
institutional study, we showed that the incidence of RP, when 
patients were treated without IMNI, was 3.3% (n= 12/366), 
with the BCS group accounting for 2.2% and the MRM group 
accounting for 4.3%. In addition, the incidence rates of grade 
1 and 2 RP after using the partial wide tangent method were 
4.9% (n = 9/185) and 2.2% (n = 4/185), respectively. In the 
MRM group, the risk of RP can be reduced by using the re-
verse hockey stick method, in which the anterior chest wall is 
irradiated with an electron beam using an individualized step-
bolus. However, 13.7% of patients experienced RP, which may 
have resulted from improper administration of the step-bolus. 
The results of the current study are in line with previous re-
ports on pulmonary toxicity associated with breast radiother-
apy [5,16,17]. Although the incidence of RP, including asymp-
tomatic radiologic changes, was significantly increased with 
IMNI, the clinical impact was minimal. In the EORTC 
22922/10925 trial, researchers found no significant difference 
between the deterioration of the performance status and in-
creased lung toxicity [5]. Thus, we suggest that IMNI can be 
applied without any significantly increased risk.
The incidence of RP correlates with the irradiated lung vol-
ume and radiation dose. A previous study suggested that if the 
ipsilateral lung irradiation volume is less than 12%, then the 
risk of pneumonitis is minimal, even with coverage of the su-
praclavicular area [18]. In general, the MLD and V20 are relat-
ed to RP, and the ipsilateral V20 can predict the risk of pulmo-
nary toxicity [19]. In the current study, each patient underwent 
CT-based simulation; therefore, we obtained and analyzed the 
relationship between the dosimetric parameters and the inci-
dence of RP with or without IMNI. MLD and V20 (17.66±  
5.33 Gy and 34.94%± 12.15%, respectively) in the IMNI group 
were higher than in the non-IMNI group (13.29± 4.37 Gy and 
25.49%± 10.53%, respectively). Other lung dosimetric para-
meters such as V10, V30, and V40 also exhibited statistically sig-
nificant differences between the two groups. A previous single-
institution study showed that the incidence of RP was higher 
in patients with MLD ≥ 20.5 Gy or a normal tissue complica-
tion probability ≥ 23% [15]. Through this large prospective 
trial, we confirmed that the incidence of RP, as evaluated using 
chest X-ray, increased with higher doses of radiation to the 
lung, which was associated with IMNI. However, clinically 
meaningful grade 2 RP was not predictable on the basis of do-
simetric parameters. Other patient factors that increase the 
risk of RP can also be considered. It has been reported that RP 
is more likely to occur when certain chemotherapy drugs are 
administered along with radiation. However, because all the 
patients in our trial received chemotherapy, we could not eval-
uate the effect of chemotherapy. 
One drawback of this study is that the chest X-ray follow-
up visit could occur at any time within 6 months after RT. 
Considering that most radiologic changes in this study were 
found at 2 or 3 months after RT, the heterogeneity of the fol-
low-up time among patients may have caused an underesti-
mation of asymptomatic grade 1 RP. Furthermore, we did not 
assess the change in performance status between the enroll-
ment and post-RT periods, which may have helped to evalu-
ate the effect of IMNI on quality-of-life. In this study, we fo-
cused only on short-term RP incidence; we did not plan to in-
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vestigate radiation-related cardiac disease, because late cardiac 
toxicity often appears 10 to 15 years after radiotherapy, mean-
ing long-term follow-up is required [20-22]. Nilsson et al. [23] 
reported that radiation to the supraclavicular lymph nodes 
and IMNs increased the risk of stroke. The EORTC trial 
22922/10925 assessed the impact of elective internal mamma-
ry and medical supraclavicular lymph node irradiation on the 
well-known toxicities of breast cancer radiotherapy, including 
lung, skin, and heart toxicity [5]. In contrast, they found that 
increased lung toxicity with IMNI was the only statistically 
significant factor between the two treatment groups at 3 years.
With newer treatment techniques, such as the breath-hold 
technique, intensity-modulated RT, particle therapy, and volu-
metric-modulated arc therapy, IMNI can be delivered at even 
lower doses to the organ at risk, especially in left-sided breast 
cancer [24-26]. Consequently, the incidence of RP and dose 
parameters with IMNI estimated in this study can be further 
decreased by including these newer methods. 
In conclusion, results from this large data collection study 
clearly showed that treatment of IMNs resulted in increased 
radiation to the lungs and a higher rate of RP, but the inci-
dence and severity of RP was minimal. Therefore, we suggest 
that IMNI is well tolerated with a very low risk of symptomat-
ic RP; however, future analyses should assess whether this mi-
nor impact on morbidity could affect long-term survival out-
comes. 
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